| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Investigative Ophthalmology & Visual Science, Vol 37, 1311-1321, Copyright © 1996 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
H Takagi, GL King, N Ferrara and LP Aiello
Research Division, Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts 02215, USA.
PURPOSE. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific angiogenic factor that serves an important role in numerous ischemic retinopathies. The authors studied the hypoxic gene regulation of two known VEGF receptors (KDR and Flt) and its mechanism in cultured bovine retinal endothelial cells (BREC). METHODS. Confluent monolayers of BREC were exposed to various oxygen concentrations using a computer-controlled, infrared, water-jacked CO2 incubator with reduced oxygen control. Northern blot analysis and 125I-VEGF binding analysis were used to identify hypoxia-induced alterations of VEGF receptor at mRNA and protein levels. RESULTS. KDR was detectable by Northern blot analysis in BREC, whereas Flt was not. Hypoxia decreased KDR gene expression in a dose-and time-dependent manner with maximal inhibition to 0.5 +/- 0.2% (P = 0.019) of normoxic control observed after 24 hours exposure to 0% oxygen and with significant inhibition at oxygen concentrations below 5%. Blockade of oxygen respiration decreased KDR mRNA expression to 58% +/- 7.1% of control (P = 0.001) after 3 hours. CPA, a stable adenosine A1 receptor (A1R) agonist, did not affect KDR mRNA expression at A1R stimulatory concentrations, but it decreased KDR mRNA levels to 30% +/- 4.9% (P = 0.002) of control at higher concentrations that react with A2R. DPMA, an adenosine A2 receptor (A2R) agonist, decreased KDR mRNA in a dose-dependent manner with an EC50 of 5 to 10 nM. A1R antagonists, 8-cyclolentyl-1,3- dipropylxanthine and 8-phenyltheophylline, did not inhibit the hypoxic response of KDR mRNA at A1R inhibitory concentrations but did inhibit the response at A2R effective doses (P = 0.001). The A2R antagonist, CSC, inhibited the KDR hypoxic response by 42% +/- 7.8% (P = 0.008) at 10 microM. Specific VEGF binding to BREC was decreased from 15.1% +/- 0.3% to 12.7% +/- 0.4% per milligram protein (P < 0.001) after exposure to 1% oxygen for 24 hours. In contrast, long-term exposure to 1% oxygen (72 hours) resulted in an increase of VEGF binding from 13.5% +/- 1.1% to 18.3% +/- 0.8% per milligram protein (P < 0.001). Scatchard analysis detected a decrease of receptor binding sites without change in binding affinity after 30 hours of exposure to hypoxia but demonstrated an increase in specific binding sites (4.2 +/- 0.6 x 10(4) sites/cell to 6.7 +/- 1.0 x 10(4) sites/cell, P = 0.049) with unaltered receptor affinity after 72 hours of hypoxic exposure. CONCLUSIONS. These data suggest that hypoxia induces an initial decline in KDR mRNA levels and VEGF binding sites as mediated through adenosine binding to the A2R. Exposure to prolonged periods of hypoxia, however, results in an increase in VEGF binding sites by an as yet unidentified mechanism.
This article has been cited by other articles:
|
|
 |
|
  D. S. Allen-Gipson, J. Wong, J. R. Spurzem, J. H. Sisson, and T. A. Wyatt Adenosine A2A receptors promote adenosine-stimulated wound healing in bronchial epithelial cells Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L849 - L855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Montesinos, J. P. Shaw, H. Yee, P. Shamamian, and B. N. Cronstein Adenosine A2A Receptor Activation Promotes Wound Neovascularization by Stimulating Angiogenesis and Vasculogenesis Am. J. Pathol., June 1, 2004; 164(6): 1887 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Afzal, L.C. Shaw, S. Caballero, P.E. Spoerri, A.S. Lewin, D. Zeng, L. Belardinelli, and M.B. Grant Reduction in Preretinal Neovascularization by Ribozymes That Cleave the A2B Adenosine Receptor mRNA Circ. Res., September 19, 2003; 93(6): 500 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Montesinos, A. Desai, J.-F. Chen, H. Yee, M. A. Schwarzschild, J. S. Fink, and B. N. Cronstein Adenosine Promotes Wound Healing and Mediates Angiogenesis in Response to Tissue Injury Via Occupancy of A2A Receptors Am. J. Pathol., June 1, 2002; 160(6): 2009 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Leibovich, J.-F. Chen, G. Pinhal-Enfield, P. C. Belem, G. Elson, A. Rosania, M. Ramanathan, C. Montesinos, M. Jacobson, M. A. Schwarzschild, et al. Synergistic Up-Regulation of Vascular Endothelial Growth Factor Expression in Murine Macrophages by Adenosine A2A Receptor Agonists and Endotoxin Am. J. Pathol., June 1, 2002; 160(6): 2231 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Burnstock Purinergic Signaling and Vascular Cell Proliferation and Death Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 364 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Mino, P. E. Spoerri, S. Caballero, D. Player, L. Belardinelli, I. Biaggioni, and M. B. Grant Adenosine Receptor Antagonists and Retinal Neovascularization in Vivo Invest. Ophthalmol. Vis. Sci., December 1, 2001; 42(13): 3320 - 3324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Joussen, S. Huang, V. Poulaki, K. Camphausen, W.-D. Beecken, B. Kirchhof, and A. P. Adamis In Vivo Retinal Gene Expression in Early Diabetes Invest. Ophthalmol. Vis. Sci., November 1, 2001; 42(12): 3047 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Grant, M. I. Davis, S. Caballero, I. Feoktistov, I. Biaggioni, and L. Belardinelli Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2B Adenosine Receptor Stimulation Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 2068 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF]
|
|
|
|
|
|
A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. P. Gavin, D. A. Spector, H. Wagner, E. C. Breen, and P. D. Wagner Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise J Appl Physiol, May 1, 2000; 88(5): 1690 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Otani, H. Takagi, H. Oh, K. Suzuma, M. Matsumura, E. Ikeda, and Y. Honda Angiotensin II-Stimulated Vascular Endothelial Growth Factor Expression in Bovine Retinal Pericytes Invest. Ophthalmol. Vis. Sci., April 1, 2000; 41(5): 1192 - 1199. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Lutty, C. Merges, and D. S. McLeod 5' Nucleotidase and Adenosine during Retinal Vasculogenesis and Oxygen-Induced Retinopathy Invest. Ophthalmol. Vis. Sci., January 1, 2000; 41(1): 218 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
M. Taomoto, D. S. McLeod, C. Merges, and G. A. Lutty Localization of Adenosine A2a Receptor in Retinal Development and Oxygen-Induced Retinopathy Invest. Ophthalmol. Vis. Sci., January 1, 2000; 41(1): 230 - 243. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Veikkola, M. Karkkainen, L. Claesson-Welsh, and K. Alitalo Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors Cancer Res., January 1, 2000; 60(2): 203 - 212. [Full Text]
|
|
|
|
|
|
M. B. Grant, R. W. Tarnuzzer, S. Caballero, M. J. Ozeck, M. I. Davis, P. E. Spoerri, I. Feoktistov, I. Biaggioni, J. C. Shryock, and L. Belardinelli Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells Circ. Res., October 15, 1999; 85(8): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Duenas, L. Torner, A. M. Corbacho, A. Ochoa, G. Gutierrez-Ospina, F. Lopez-Barrera, F. A. Barrios, P. Berger, Gonzalo Martinez de la Escalera, and C. Carmen Inhibition of Rat Corneal Angiogenesis by 16-kDa Prolactin and by Endogenous Prolactin-like Molecules Invest. Ophthalmol. Vis. Sci., October 1, 1999; 40(11): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Suzuma, M. Mandai, H. Takagi, K. Suzuma, A. Otani, H. Oh, K. Kobayashi, and Y. Honda 17 {beta}-Estradiol Increases VEGF Receptor-2 and Promotes DNA Synthesis in Retinal Microvascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 2122 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Smith, D. McLeod, D. Foreman, and M. Boulton Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy Br. J. Ophthalmol., April 1, 1999; 83(4): 486 - 494. [Abstract] [Full Text]
|
|
|
|
|
|
G. HÓLLÓ;, A. IANNACCONE, and C. LETIZIA Plasma endothelin-1 concentrations in patients with retinal vein occlusions Br. J. Ophthalmol., January 1, 1999; 83(1): 126c - 126. [Full Text]
|
|
|
|
 |
|
 Y. Hata, E. Duh, K. Zhang, G. S. Robinson, and L. P. Aiello Transcription Factors Sp1 and Sp3 Alter Vascular Endothelial Growth Factor Receptor Expression through a Novel Recognition Sequence J. Biol. Chem., July 24, 1998; 273(30): 19294 - 19303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Cheung Vascular Endothelial Growth Factor: Possible Role in Fetal Development and Placental Function Reproductive Sciences, July 1, 1997; 4(4): 169 - 177. [Abstract] [PDF]
|
|
|
|
|
|
R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br. J. Ophthalmol., June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferrara and T. Davis-Smyth The Biology of Vascular Endothelial Growth Factor Endocr. Rev., February 1, 1997; 18(1): 4 - 25. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
